Cue Biopharma Stock Market Value
| CUE Stock | USD 1.04 0.04 3.70% |
| Symbol | Cue |
Cue Biopharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cue Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cue Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cue Biopharma.
| 10/31/2024 |
| 12/30/2024 |
If you would invest 0.00 in Cue Biopharma on October 31, 2024 and sell it all today you would earn a total of 0.00 from holding Cue Biopharma or generate 0.0% return on investment in Cue Biopharma over 60 days. Cue Biopharma is related to or competes with Coya Therapeutics,, Lantern Pharma, Fennec Pharmaceuticals, Anixa Biosciences, INmune Bio, In8bio, and PolyPid. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of... More
Cue Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cue Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cue Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.68 | |||
| Information Ratio | 0.147 | |||
| Maximum Drawdown | 67.78 | |||
| Value At Risk | (11.51) | |||
| Potential Upside | 20.27 |
Cue Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cue Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cue Biopharma's standard deviation. In reality, there are many statistical measures that can use Cue Biopharma historical prices to predict the future Cue Biopharma's volatility.| Risk Adjusted Performance | 0.1287 | |||
| Jensen Alpha | 1.78 | |||
| Total Risk Alpha | 1.44 | |||
| Sortino Ratio | 0.2611 | |||
| Treynor Ratio | (4.61) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma Backtested Returns
Cue Biopharma is dangerous given 3 months investment horizon. Cue Biopharma secures Sharpe Ratio (or Efficiency) of 0.1, which signifies that the company had a 0.1% return per unit of standard deviation over the last 3 months. We are able to break down and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.05% are justified by taking the suggested risk. Use Cue Biopharma risk adjusted performance of 0.1287, and Mean Deviation of 7.94 to evaluate company specific risk that cannot be diversified away. Cue Biopharma holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.38, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cue Biopharma are expected to decrease at a much lower rate. During the bear market, Cue Biopharma is likely to outperform the market. Use Cue Biopharma potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to analyze future returns on Cue Biopharma.
Auto-correlation | 0.46 |
Average predictability
Cue Biopharma has average predictability. Overlapping area represents the amount of predictability between Cue Biopharma time series from 31st of October 2024 to 30th of November 2024 and 30th of November 2024 to 30th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cue Biopharma price movement. The serial correlation of 0.46 indicates that about 46.0% of current Cue Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Cue Biopharma lagged returns against current returns
Autocorrelation, which is Cue Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cue Biopharma's stock expected returns. We can calculate the autocorrelation of Cue Biopharma returns to help us make a trade decision. For example, suppose you find that Cue Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cue Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cue Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cue Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cue Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
Cue Biopharma Lagged Returns
When evaluating Cue Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cue Biopharma stock have on its future price. Cue Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cue Biopharma autocorrelation shows the relationship between Cue Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in Cue Biopharma.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Cue Biopharma Correlation, Cue Biopharma Volatility and Cue Biopharma Alpha and Beta module to complement your research on Cue Biopharma. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.